Registration Strip Icon for default 登録して無料でリアルタイムの株価、インタラクティブチャート、ライブオプションフローなどを入手してください。

PSTX

Poseida Therapeutics (PSTX)

Poseida Therapeutics Inc
から:
次の項目別のソート:
 Showing the most relevant articles for your search:NASDAQ:PSTX
日付受信時刻ニュースソース見出しコード企業名
2024/06/0405 : 05PR Newswire (US)Poseida Therapeutics Announces Virtual 2024 Annual Meeting of StockholdersNASDAQ:PSTXPoseida Therapeutics Inc
2024/05/1505 : 11Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:PSTXPoseida Therapeutics Inc
2024/05/1505 : 06Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:PSTXPoseida Therapeutics Inc
2024/05/1505 : 05PR Newswire (US)Poseida Therapeutics Provides Updates and Financial Results for the First Quarter of 2024NASDAQ:PSTXPoseida Therapeutics Inc
2024/05/0922 : 00PR Newswire (US)Poseida Highlights Strong Progress on Its Genetic Medicine Programs at the American Society for Gene and Cell Therapy 27th Annual MeetingNASDAQ:PSTXPoseida Therapeutics Inc
2024/05/0613 : 15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:PSTXPoseida Therapeutics Inc
2024/05/0210 : 30PR Newswire (US)Astellas and Poseida Therapeutics Enter Into Research Collaboration and License Agreement to Develop Novel Allogeneic Cell Therapies in OncologyNASDAQ:PSTXPoseida Therapeutics Inc
2024/05/0204 : 25AllPennyStocks.comBiotech Soars on Research Collaboration And License Agreement ReleaseNASDAQ:PSTXPoseida Therapeutics Inc
2024/05/0122 : 00PR Newswire (US)Astellas and Poseida Therapeutics Enter Into Research Collaboration and License Agreement to Develop Novel Allogeneic Cell Therapies in OncologyNASDAQ:PSTXPoseida Therapeutics Inc
2024/04/1821 : 00PR Newswire (US)Poseida Therapeutics Announces Strong Lineup of Presentations at the American Society of Gene and Cell Therapy 27th Annual MeetingNASDAQ:PSTXPoseida Therapeutics Inc
2024/04/1722 : 00PR Newswire (US)Poseida Therapeutics Hosts Gene Therapy R&D Day Highlighting New Scientific Advancements and Pipeline FocusNASDAQ:PSTXPoseida Therapeutics Inc
2024/04/0901 : 00PR Newswire (US)Poseida Therapeutics Presents New Phase 1 Data at AACR 2024 Supporting Potential of P-BCMA-ALLO1 Allogeneic CAR-T Therapy to Benefit Broad Range of Patients with Multiple MyelomaNASDAQ:PSTXPoseida Therapeutics Inc
2024/04/0205 : 05PR Newswire (US)Poseida Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:PSTXPoseida Therapeutics Inc
2024/03/2605 : 05PR Newswire (US)Poseida Therapeutics Appoints Syed Rizvi, M.D., as Chief Medical OfficerNASDAQ:PSTXPoseida Therapeutics Inc
2024/03/2005 : 05PR Newswire (US)Poseida Therapeutics to Present at H.C. Wainwright 2nd Annual Cell Therapy Virtual ConferenceNASDAQ:PSTXPoseida Therapeutics Inc
2024/03/1405 : 05PR Newswire (US)Poseida Therapeutics Announces FDA Orphan Drug Designation Granted to P-BCMA-ALLO1 for the Treatment of Multiple MyelomaNASDAQ:PSTXPoseida Therapeutics Inc
2024/03/0806 : 07PR Newswire (US)Poseida Therapeutics Provides Updates and Financial Results for the Fourth Quarter and Full Year 2023NASDAQ:PSTXPoseida Therapeutics Inc
2024/03/0806 : 05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:PSTXPoseida Therapeutics Inc
2024/03/0507 : 29Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:PSTXPoseida Therapeutics Inc
2024/03/0507 : 18Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:PSTXPoseida Therapeutics Inc
2024/03/0506 : 05PR Newswire (US)Poseida Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:PSTXPoseida Therapeutics Inc
2024/02/0906 : 10Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:PSTXPoseida Therapeutics Inc
2024/01/0506 : 03Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:PSTXPoseida Therapeutics Inc
2024/01/0506 : 01Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:PSTXPoseida Therapeutics Inc
2024/01/0422 : 00PR Newswire (US)Poseida Therapeutics Highlights Recent Progress, Strategic Priorities and Anticipated 2024 Key MilestonesNASDAQ:PSTXPoseida Therapeutics Inc
2023/12/1200 : 31Dow Jones NewsPoseida Therapeutics Shares Climb on Positive Data for Blood Cancer TreatmentNASDAQ:PSTXPoseida Therapeutics Inc
2023/12/1120 : 06Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:PSTXPoseida Therapeutics Inc
2023/12/1102 : 00PR Newswire (US)Poseida Therapeutics Presents Positive Early Results from its Phase 1 Trial of Allogeneic CAR-T P-BCMA-ALLO1 in Relapsed-Refractory Multiple Myeloma at the 65th American Society of Hematology (ASH) Annual MeetingNASDAQ:PSTXPoseida Therapeutics Inc
2023/11/1006 : 11Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:PSTXPoseida Therapeutics Inc
2023/11/1006 : 05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:PSTXPoseida Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:PSTX

最近閲覧した銘柄

Delayed Upgrade Clock